uliledlimab — Interim data
2H 2026
Uliledlimab CD73 mAb NSCLC Uli + PD-(L)1 ± Chemo NCT06984588 Phase 1b/2 PFS data 2H 20265 Global (ex-Greater China)Source filing
NBP biotech catalysts & pipeline
NOVABRIDGE BIOSCIENCES · Data as of 2026-10-25
Upcoming catalysts
givastomig — Clinical data readout
Late 2027
We intend to use the net proceeds from the Offering, together with our existing cash and cash equivalents, to fund ongoing clinical development of our pipeline product candidates, including a randomized Phase 2 trial of givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, intended to have sufficient power and size to generate clinically meaningful progression-free survival (PFS) data by end of 2027, and for working capital and other general corporate purposes.Source filing
givastomig — Conference presentation
H2 2026
"We expect to present results from this study in 2027. In addition, we expect to present updated results from the Phase 1b dose expansion study in the second half of this year."Source filing
givastomig — Conference presentation
Oct 25
Presentation Details Title: Expanded Safety and Efficacy of Givastomig, a Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in 1L Metastatic Gastroesophageal Carcinoma (mGEC) Presentation Number: 2945P Presenter: Samuel J. Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital Date: Sunday, October 25, 2026 Time: 12:00 p.m. - 12:45 p.m. CET Location: Poster Area, Hall 5Source filing